Free Trial
NYSE:COR

Cencora (COR) Stock Price, News & Analysis

Cencora logo
$294.24 -5.61 (-1.87%)
As of 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Cencora Stock (NYSE:COR)

Key Stats

Today's Range
$292.18
$302.53
50-Day Range
$278.35
$304.04
52-Week Range
$218.65
$309.35
Volume
473,357 shs
Average Volume
1.50 million shs
Market Capitalization
$57.03 billion
P/E Ratio
34.13
Dividend Yield
0.75%
Price Target
$306.33
Consensus Rating
Moderate Buy

Company Overview

Cencora (NYSE: COR) is a leading global pharmaceutical distribution and services company, offering a comprehensive range of supply chain solutions to healthcare providers, biotechnology firms, and pharmaceutical manufacturers. The company specializes in the procurement, storage, and delivery of branded and generic pharmaceuticals, over-the-counter healthcare products, and specialty medications. Through a network of distribution centers and technology-driven logistics systems, Cencora ensures continuity of supply for a broad spectrum of therapeutic categories, supporting hospitals, pharmacies, and long-term care facilities worldwide.

In addition to its core distribution business, Cencora provides a suite of value-added services designed to enhance patient access and optimize medication management. These services include specialty pharmacy operations, medication adherence programs, patient support services, and regulatory compliance consulting. Cencora’s strategic partnerships with drug developers and biotech companies facilitate the launch of novel therapies, while its data analytics capabilities enable real-time visibility across the supply chain, helping clients navigate complex market dynamics and regulatory environments.

Originally formed in 2001 through the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, the company operated for many years under the AmerisourceBergen name. In October 2023, it rebranded as Cencora to reflect its broadened mission of connecting healthcare to people around the globe. Headquartered in Warrendale, Pennsylvania, Cencora maintains operations across North America, Europe, Asia Pacific, and select emerging markets, operating hundreds of distribution centers that adhere to stringent quality and safety standards.

Under the leadership of Chairman and Chief Executive Officer Steven H. Collis, Cencora continues to pursue strategic growth through acquisitions, technological innovation, and expanded service offerings. The company’s executive team emphasizes sustainability initiatives, digital transformation, and workforce development as key pillars for future growth. With a focus on strengthening global healthcare infrastructure and improving patient outcomes, Cencora remains a pivotal partner for stakeholders throughout the pharmaceutical value chain.

AI Generated. May Contain Errors.

Cencora Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

COR MarketRank™: 

Cencora scored higher than 93% of companies evaluated by MarketBeat, and ranked 79th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cencora has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cencora's stock forecast and price target.
  • Earnings Growth

    Earnings for Cencora are expected to grow by 9.82% in the coming year, from $15.37 to $16.88 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cencora is 34.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.81.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cencora is 34.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.42.

  • Price to Earnings Growth Ratio

    Cencora has a PEG Ratio of 1.48. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Cencora has a P/B Ratio of 74.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cencora's valuation and earnings.
  • Percentage of Shares Shorted

    3.61% of the float of Cencora has been sold short.
  • Short Interest Ratio / Days to Cover

    Cencora has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cencora has recently increased by 0.76%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cencora has a dividend yield of 0.73%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Cencora has been increasing its dividend for 15 years.

  • Dividend Coverage

    The dividend payout ratio of Cencora is 25.52%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Cencora will have a dividend payout ratio of 13.03% next year. This indicates that Cencora will be able to sustain or increase its dividend.

  • Read more about Cencora's dividend.
  • Percentage of Shares Shorted

    3.61% of the float of Cencora has been sold short.
  • Short Interest Ratio / Days to Cover

    Cencora has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cencora has recently increased by 0.76%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Cencora has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 36 news articles for Cencora this week, compared to 21 articles on an average week.
  • Search Interest

    Only 5 people have searched for COR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cencora insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,812,296.00 in company stock.

  • Percentage Held by Insiders

    10.80% of the stock of Cencora is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cencora's insider trading history.
Receive COR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.

COR Stock News Headlines

A grave, grave error.
President Donald Trump made headlines last month with a staggering claim. He stated that since taking office, more than $12 trillion in private investments into America have been “practically committed” on his watch. "Nobody's ever seen numbers like we have," he said, crediting his agenda of tariffs, tax cuts, and deregulation with making the difference. If true, the figure would indeed be astonishing – potentially tripling the roughly $4 trillion in gross private investment the US reported all of last year.
6 Analysts Have This To Say About Cencora
Goldman Sachs Mid Cap Value Fund Q1 2025 Commentary
See More Headlines

COR Stock Analysis - Frequently Asked Questions

Cencora's stock was trading at $224.68 at the beginning of the year. Since then, COR shares have increased by 33.9% and is now trading at $300.8340.
View the best growth stocks for 2025 here
.

Cencora, Inc. (NYSE:COR) announced its quarterly earnings data on Wednesday, May, 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora's revenue was up 10.3% compared to the same quarter last year.
Read the conference call transcript
.

Cencora subsidiaries include these companies: Alliance Healthcare, H. D. Smith, St. Francis Group, PharMEDium Healthcare, MWI Veterinary Supply, World Courier, IntrinsiQ, and others.

Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cencora investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Broadcom (AVGO), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

Last Earnings
5/07/2025
Record date for 6/2 Dividend
5/16/2025
Ex-Dividend for 6/2 Dividend
5/16/2025
Dividend Payable
6/02/2025
Today
7/01/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Medical Services
Sub-Industry
Health Care Distributors
Current Symbol
NYSE:COR
Employees
46,000
Year Founded
2001

Price Target and Rating

Average Stock Price Target
$306.33
High Stock Price Target
$355.00
Low Stock Price Target
$275.00
Potential Upside/Downside
+2.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
34.74
Forward P/E Ratio
19.48
P/E Growth
1.48
Net Income
$1.51 billion
Pretax Margin
0.74%

Debt

Sales & Book Value

Annual Sales
$293.96 billion
Cash Flow
$19.89 per share
Price / Cash Flow
15.06
Book Value
$4.04 per share
Price / Book
74.13

Miscellaneous

Free Float
172,890,000
Market Cap
$58.05 billion
Optionable
Optionable
Beta
0.58

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NYSE:COR) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners